ORLANDO — Ralinepag, a prostacyclin receptor agonist, added to background therapy decreased the risk for a clinical worsening event in patients with pulmonary arterial hypertension, according to phase 3 ADVANCE OUTCOMES trial results.
These findings were presented at the American Thoracic Society International Conference.
“The primary efficacy endpoint of delayed time to first clinical worsening event was met,” Vallerie V. McLaughlin, MD, Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine, director of the pulmonary hypertension program at University of Michigan and chair of the

Machine learning models could help clinicians estimate individualized risk for major complications among women undergoing postmastectomy reconstruction.
An analysis of more than 400 patients showed machine learning could help predict risk for unplanned reoperations or rehospitalizations within a year of their reconstruction, with the strongest predictors including established risk factors such as age, BMI and smoking.
“We expect these models to eventually support a more patient-centered approach to reconstructive decision-making,” Mohammed S. Shaheen, JD, medical student at Stanford Medicine,

CHICAGO — For patients with short bowel syndrome, reduced time on parenteral support may mitigate burdens such as central line complications, fatigue and decreased quality of life, according to a survey of health care professionals.
Results, presented at Digestive Disease Week, indicated that limiting the days per week and hours per day that patients spend receiving total parenteral nutrition (TPN) may benefit those with short bowel syndrome (SBS) reliant on this support.
“Reducing the risks associated with parenteral support — especially central venous access complications — should be a